Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme: Clinical article

Journal of Neurosurgery

Volumn 112, Issue 1, 2010, Pages 50-56

  Aoki, Tomokazu ^a   Mizutani, Tomohiko ^d   Nojima, Kuniharu ^e   Takagi, Takehisa ^a   Okumura, Ryosuke ^a   Yuba, Yoshiaki ^a   Ueba, Tetsuya ^b   Takahashi, Jun A ^a   Miyatake, Shin Ichi ^c   Nozaki, Kazuhiko ^f   Taki, Waro ^g   Matsutani, Masao ^h  

^a Kitano Hospital   (Japan)

^b Kishiwada City Hospital   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

^d HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

^e Ako City Hospital   (Japan)

^f SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^g MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Carboplatin; Chemotherapy; Etoposide; Glioblastoma multiforme; Ifosfamide

Indexed keywords

AMINOTRANSFERASE; CARBOPLATIN; CREATININE; ETOPOSIDE; IFOSFAMIDE; NIMUSTINE; TEMOZOLOMIDE;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BRAIN SURGERY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONVULSION; DIARRHEA; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLIOBLASTOMA; HEMORRHAGIC CYSTITIS; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LUNG EMBOLISM; LUNG INFECTION; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; GLIOBLASTOMA; HUMANS; IFOSFAMIDE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75749138606     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2009.5.JNS081738     Document Type: Article

References (34)

1. Aoki T, Hashimoto N, Matsutani M: Management of glioblastoma. Expert Opin Pharmacother 8:3133-3146, 2007
2. Aoki T, Takahashi JA, Ueba T, Oya N, Hiraoka M, Matsui K, et al: Phase II study of nimustine, carboplatin, vincristine, and interferon-b with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. J Neurosurg 105:385-391, 2006
3. Brada M, Hoang-Xuan K, Ramoling R, Dietrich PY, Dirix LY, Macdonald D, et al: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259-266, 2001
4. Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, et al: First line chemotherapy with cisplatin plus fractionated temozolomide (bid) in recurrent glioblastoma multiforme. A phase II study of the Gruppo Italiano Cooperativo Neuro-Oncologia (GICNO). J Clin Oncol 22:1598-1604, 2004
5. Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, et al: Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after fine-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperatvo di Neuro-Oncologia (GICNO). J Clin Oncol 22:4779-4786, 2004
6. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, et al: Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155-1160, 2006
7. Brandes AA, Tosoni AT, Spagnolli F, Frezza G, Leonardi M, Calbucci F, et al: Disease progression or pseudoprogression after concomitant radiochemotheray treatment: pitfalls in neurooncology. Neuro Oncol 10:361-367, 2008
8. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ: Clinical features, mechanisms, and management of pseudo-progression in malignant gliomas. Lancet Oncol 9:453-461, 2008
9. Butowski NA, Sneed PK, Chang SM: Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 24:1273-1280, 2006
10. Chamberlain MC: Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol 26:1012-1013, 2008
11. Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, Schiff D, et al: A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glio-blastoma (GBM). J Clin Oncol 26 (Suppl):2010b, 2008 (Abstract)
12. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, et al: Phase II study trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21: 2299-2304, 2003
13. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, et al: Phase II trial of temozolomide plus matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20:1383-1388, 2002
14. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
15. Jaeckle KA, Hess KR, Yung A, Greenberg H, Fine H, Schiff D, et al: Phase II evaluation of temozolomide and 13-cis retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium Study. J Clin Oncol 21:2305-2311, 2003
16. Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Milojevic L, Djuric L, et al: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 10:1074-1077, 1992
17. Kappelle AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, van den Bent MJ, van Groeningen CJ, et al: PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56:118-120, 2001
18. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
19. Marina NM, Rodman J, Shema SJ, Bowman LC, Douglass E, Furman W, et al: Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol 11:554-560, 1993
20. Sanson M, Ameri A, Monjour A, Sahmoud T, Ronchin P, Poisson M, et al: Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur J Cancer 32A:2229-2235, 1996
21. Schrag D, Hanger M: Medical oncologists' view on communicationg with patients about chemotherapy costs: a pilot survey. J Clin Oncol 25:233-237, 2007
22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
23. Takahashi Y, Nishioka K: Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy. J Natl Cancer Inst 87:1262-1263, 1995
24. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al: Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004-1011, 2003
25. Vecht CJ, Wagner GL, Wilms EB: Interractions between anti-epileptic and chemotherapeutic drugs. Lancet Neurol 2:404-409, 2003
26. Vredenburgh JJ, Desjardins A, Herndon JE II, Dowell JM, Reardon DA, Quinn JA, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259, 2007
27. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729, 2007
28. Wasserfallen JB, Ostermann S, Leyvraz S, Stupp R: Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. Neuro Oncol 7:189-195, 2005
29. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5: 79-88, 2003
30. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, et al: Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357-3361, 2007
31. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999
32. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593, 2000
33. Yung WK, Mechtler L, Gleason MJ: Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9:860-864, 1991
34. Zalupski M, Baker LH: Ifosfamide. J Natl Cancer Inst 80: 556-566, 1988